Work

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting

Year: 2026

Type: article

Abstract: Current Myeloproliferative neoplasm (MPN) therapies provide meaningful symptom and event-risk control but are limited by infrequent molecular remissions, treatment-limiting cytopenias (particularly anemia), and continued reliance on non-mutation-directed cytoreduction or phlebotomy with attendant morbidity. At ASH 2025 Annual Meeting, multiple investigational strategies aimed to address these limitations, including clone-directed targeting (INCA033989), phlebotomy-sparing physiologic therapy (rusfertide), and epigenetic disease-modifying combinations (pelabresib). We summarized the latest updates on these emerging agents and regimens for MPNs from the 2025 ASH Annual Meeting.

Source: Experimental Hematology and Oncology

DOI: 10.1186/s40164-026-00813-0

Authors: Tiantian Zhang, Heng Jiang, Delong Liu

Institutions: University of Central Florida, Westchester Medical Center, New York Medical College

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,290